Elucidata (MA)

We support discovery programs at Pfizer, Genentech, Janssen Pharmaceuticals, Stanford and Yale and over 35 research partners from premier biopharma companies and research labs. We are a 150+ multi-disciplinary team of experts based across the US, Canada, and India. In September 2022, we raised $16 million in our Series A round led by Eight Roads and F-Prime along with our old investors Hyperplane and IvyCap. We have developed Polly, an industry-leading data-centric MLOps platform for life sciences. Its technology cleans and links biomedical data at scale into an ML-ready form. Polly delivers 90+ TB of biomedical data from ~30 different sources to customers. The platform helps data science teams scale up by providing them with curated ML-ready biomolecular data from public and proprietary sources. Inspired by the FAIR guidelines described by the NIH, Polly's OmixAtlases allow exclusive access to curated multi-omics data that is ready for ML workflows. Polly offers 10x faster identification of therapeutic assets with high odds of success in the clinic. It has enabled the detection of multiple validated drug targets across immunology, oncology, and metabolic disorders.

Active/Inactive	Active
CIN	U74999DL2016PTC292977
Office Location	New Delhi, India
Incorporation Year	2015(9 yrs old)
Industry	IT Services
Company Employees	51-200
Website	www.elucidata.io
Avg Revenue	$ 50M - 100M
Social Profile